INSILICO (03696) collaborates with Zhejiang Hisun Pharmaceutical (600267.SH) to accelerate AI research and development, delivering a key milestone in 8 months.

Clinical stage drug development technology company INSILICO (03696), driven by generative artificial intelligence, announced a milestone in the innovative drug development project in collaboration with Zhejiang Hisun Pharmaceutical (600267.SH). Leveraging the company's self-developed artificial intelligence drug development platform Pharma.AI, the two parties have nominated a preclinical candidate compound (PCC) for the collaboration project within about 8 months of reaching a strategic partnership. Public information shows that the collaboration began in April 2025. Xiao Weihong, Chairman and CEO of Zhejiang Hisun Pharmaceutical, and Ren Feng, Co-CEO and Chief Scientific Officer of INSILICO, signed the innovative drug research and development strategic cooperation agreement at the research headquarters of Zhejiang Hisun Pharmaceutical. According to the agreement, both parties will collaborate deeply in specific therapeutic areas around selected targets, combining artificial intelligence technology with traditional drug development advantages to accelerate the discovery and development of innovative drugs. In terms of specific responsibilities, INSILICO is mainly responsible for early-stage research ranging from target identification to PCC nomination, including AI-based target analysis, lead compound discovery and structure optimization, as well as key preclinical studies; Zhejiang Hisun Pharmaceutical is responsible for supporting the relevant research for new drug clinical trial applications (IND) and advancing subsequent clinical trial application and implementation. It is reported that within 8 months of the collaboration, INSILICO efficiently advanced the early-stage research of the project with its Pharma.AI platform and completed the preclinical studies required to support the PCC nomination. The preclinical data generated by the project has been evaluated internally by Zhejiang Hisun Pharmaceutical and meets the PCC nomination standards set by both parties. According to the established arrangement, Zhejiang Hisun Pharmaceutical will lead the project going forward. INSILICO stated that the collaboration with Zhejiang Hisun Pharmaceutical reaching the first milestone in a short period of time is another vivid example of AI-driven innovation in early drug development. Focusing on relatively novel targets and addressing areas of diseases with significant unmet clinical needs, this collaboration demonstrates the potential for AI innovation. With the support of the Pharma.AI platform, INSILICO is committed to systematically exploring a broad biological and chemical space in a shorter time frame to bring more innovative treatment options to patients. Zhejiang Hisun Pharmaceutical expressed deep impressions on the efficiency and quality of the nomination of preclinical candidate compounds within 8 months of this collaboration project, demonstrating the acceleration and effectiveness of AI in the drug development process. The collaboration with INSILICO not only enhances Zhejiang Hisun Pharmaceutical's innovation capability in early drug development projects, but also marks a key step in the company's digital and intelligent transformation. Zhejiang Hisun Pharmaceutical believes that integrating traditional pharmaceutical experience with cutting-edge AI technology will help the company strategically position with higher quality and efficiency in innovation pipeline, continuously providing more valuable treatment options for patients. The nomination of PCC in a short period of time in this collaboration is a validation of INSILICO's delivery capability and the efficiency of collaboration between the two parties, reflecting the potential advantages of generative artificial intelligence in improving the efficiency, shortening the development cycle, and optimizing costs in innovative drug development. It also provides a representative case for domestic enterprises to explore new paths in drug development through the collaborative model of "AI platform + pharmaceutical industrialization capabilities."